Onconova Therapeutics Inc - ESG Rating & Company Profile powered by AI
Comprehensive Sustainability assessment of Onconova Therapeutics Inc can be reached by signing in. Other companies in the scoring industry group for Onconova Therapeutics Inc are displayed. If you are employed by Onconova Therapeutics Inc and you would like to use your ESG rating, please get in touch.
Onconova Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.6; made up of an environmental score of 3.2, social score of 4.0 and governance score of 5.7.
4.6
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Novartis AG | 9.2 | High |
2 | Daiichi Sankyo Co Ltd | 8.9 | High |
1156 | Vectus Biosystems Ltd | 4.7 | High |
1156 | Zynerba Pharmaceuticals Inc | 4.7 | High |
1199 | Onconova Therapeutics Inc | 4.6 | High |
1199 | Allergan Inc | 4.6 | High |
1199 | AroCell AB (publ) | 4.6 | High |
... | ... | ... | |
2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
2749 | Zyden Gentec Ltd | 0.0 | Low |
... | ... | ... |
Frequently Asked Questions
Does Onconova Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Onconova Therapeutics Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Onconova Therapeutics Inc report the average age of the workforce?
Sign up for free to unlockDoes Onconova Therapeutics Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Onconova Therapeutics Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Onconova Therapeutics Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Onconova Therapeutics Inc offer flexible work?
Sign up for free to unlockDoes Onconova Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Onconova Therapeutics Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Onconova Therapeutics Inc conduct supply chain audits?
Sign up for free to unlockDoes Onconova Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Onconova Therapeutics Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Onconova Therapeutics Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Onconova Therapeutics Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Onconova Therapeutics Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Onconova Therapeutics Inc disclose water use targets?
Sign up for free to unlockDoes Onconova Therapeutics Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Onconova Therapeutics Inc have a product recall in the last two years?
Sign up for free to unlockDoes Onconova Therapeutics Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Onconova Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Onconova Therapeutics Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Onconova Therapeutics Inc disclose parental leave metrics?
Sign up for free to unlockDoes Onconova Therapeutics Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Onconova Therapeutics Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Onconova Therapeutics Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Onconova Therapeutics Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Onconova Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Onconova Therapeutics Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Onconova Therapeutics Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Onconova Therapeutics Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Onconova Therapeutics Inc disclose its waste policy?
Sign up for free to unlockDoes Onconova Therapeutics Inc report according to TCFD requirements?
Sign up for free to unlockDoes Onconova Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Onconova Therapeutics Inc disclose energy use targets?
Sign up for free to unlockDoes Onconova Therapeutics Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Onconova Therapeutics Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Onconova Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company develops a Phase Ib/II ISS with rigosertib monotherapy in patients with advanced squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa; and has a preclinical program comprising IV/oral rigosertib for COVID-19. It has a license agreement with SymBio Pharmaceuticals Limited; license, development, and commercialization agreement with Pint International SA.; and a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.